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stantially increase the aggregate health ofMedicare beneficiarieswhile not increasing
Medicare spending. The reallocation resulted in a greater proportion of resources di-
rected towards diagnostics tests, more prevalent diseases, and oncology.
MD2
PRESCRIPTION DRUG COST AND USE IN THE MEDICARE PART D
POPULATION - USES OF A NEW LIMITED DATA SET
Powers CA1, Varghese A1, Hsu VD2, O’Donnell J3, Schneider K3
1Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA, 2Buccaneer, A Vangent
Company, Owings Mills, MD, USA, 3Buccaneer, A Vangent Company, West Des Moines, IA, USA
OBJECTIVES:While Medicare Part D research identifiable files have been available
to academic researchers for some time, a new limited data set (LDS) containing Part
D drug utilization and cost information is now available to both academic and
non-academic researchers. This study was undertaken to demonstrate the versa-
tility of LDS in analyzing drug utilization and cost.METHODS: Aged Medicare ben-
eficiaries alive for all of 2008 with 12 months of Part A, B, and D coverage were
selected. The average number of prescription drug fills (30-day adjusted) and aver-
age costs permember permonth (PMPM)were calculated overall, by demographics,
and for selected chronic conditions. Specific drug use was also examined for a
chronic condition of interest. RESULTS: Overall, the average PMPM number of fills
was 4.3 and the cost was $212, beneficiaries took 8.9 distinct medications, and
mean cost per fill was $49.75. Older beneficiaries filled more prescriptions per
month (4.9 for 85 years vs. 3.9 for 65-74 years), but had lower mean costs per fill
($46.95 for85 years vs. $51.61 for 65-74 years). Females had higher PMPM fills (4.5
vs. 3.9) and costs ($220 vs. $198) compared to males. Dual-eligible Medicare and
Medicaid beneficiaries had approximately 1.5 times higher PMPM fills and costs
compared to beneficiaries without any Part D subsidies. PMPM fills and costs also
vary with race. Compared to the overall Medicare cohort, beneficiaries with the
selected chronic conditions had higher PMPM fills and costs: diabetes (6.0, $303),
Alzheimer’s (6.0, $358), depression (6.4, $357), and osteoporosis (4.8, $261). Patterns
of use and cost by demographics differed by condition compared to the overall
cohort, except by dual eligible status. CONCLUSIONS: As demonstrated, the new
Part D LDS data allows researchers to conduct utilization and cost studies using all
and subsets of Medicare beneficiaries with selected chronic conditions.
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OBJECTIVES:Medicare Part D allows each beneficiary the ability to choose and enroll
in a privately sponsored Medicare-approved prescription drug plan (PDP). However,
with 33 different stand-alone PDPs to choose from in California in 2011 alone, such a
choice can be overwhelming. We sought to assist beneficiaries with Part D plan eval-
uation and quantify their willingness-to-pay (WTP) for such services during the 2011
open enrollment period.METHODS: Nine outreach events were held in cities across
central/northern California during which 395 beneficiaries were assisted with their
Medicare Part D plan. During each session, beneficiary-specific information (e.g.,
prescription medications) was entered into the Medicare Plan Finder Tool (www.
medicare.gov) to help facilitate the intervention. Demographic and plan-specific data,
along with the results of the intervention, were collected from each assisted benefi-
ciary. At the conclusion of the session, each beneficiary’sWTPwas elicited. RESULTS:
Of the 348 (88.1%) beneficiaries who answered the question, the median (mean) WTP
for Part D plan help was $20 ($40.04). A significant difference (p0.001) was found in
the WTP of beneficiaries as a function of whether or not they received additional
governmental assistance (e.g., Medicaid). The median (mean) WTP of 96 subsidy-re-
cipients was $0 ($12.43) versus $25 ($51.38) for 247 non-subsidy recipients. WTP was
also dependent (p0.01) on whether or not the beneficiary was enrolled into a new
plan during the interventional session. Themedian (mean)WTP of the 126 beneficia-
ries that were enrolled into a PDP plan onsite was $25 ($57.79) versus $10 ($30.00) for
the 220 beneficiaries who were not. Finally, beneficiaries’ WTP was significantly cor-
related (rs 0.235; p0.001) with the estimated annual cost savings identified during
the intervention. CONCLUSIONS: Beneficiaries valueMedicare Part D plan assistance
and the perceived value varies as a function of certain demographic and interven-
tional characteristics.
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OBJECTIVES: The objective of this study was to evaluate the relationship between
a physician-based intervention and the reduction in poly-pharmacy for a segment
of a national managed care Medicare Part D cohort.METHODS: Providers of Medi-
care Part D members in 2009 were sent a letter if one or more of their patients met
the criteria for both medication therapy management (MTM) and poly-pharmacy.
The providers were asked to review the member’s prescription profile and make
appropriate changes based solely on the provider’s clinical judgement. Two fol-
low-up quarters were defined for each member in 2009, and two baseline quarters
were defined in 2008. From prescription claims, fields were collected allowing the
creation of change variables. Changes in claim count, drug (GPI) count, and medi-
cation cost were evaluated using feasible generalized least squares and a linear
probability model (change in claim and drug count). The intervention cohort was
compared to a control cohort, consisting of Medicare Part D members who met
poly-pharmacy criteria but not MTM program criteria. RESULTS: The analysis re-
vealed a significantly greater reduction of 3.72 claims (second baseline quarter 2008
versus second follow-up quarter 2009. p  0.001) for the intervention. There was a
significantly greater reduction of 1.67 drugs (GPI8) for the intervention (p  0.001).
Medication costs for the intervention were decreased $204 (ingredient cost, $149 in
amount paid for medications, p  0.001 for both medication costs). The linear
probability model showed the intervention was associated with a 4.4%, 6.5%, and
12.9% significantly greater probability of a three to five, six to eight, and a greater
than eight, respectively, claim count reduction (p  0.001). The intervention was
also associated with a significantly greater probability of drug count reduction (p
0.001). CONCLUSIONS: The intervention was associated with a statistically signif-
icant marginal reduction in claim count, drug count, and medication costs com-
pared to a control Medicare Part D cohort.
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OBJECTIVES: A within-trial analysis examined the cost-effectiveness of dutas-
teride as a chemoprevention comparedwith placebo, by analyzing the resource use
incurred by men in Reduction by Dutasteride of Prostate Cancer Events (REDUCE)
trial. METHODS: REDUCE was a 4-year, randomized, double-blind, placebo-con-
trolled, parallel-group trial to compare the efficacy and safety of dutasteride 0.5mg
daily with placebo for chemoprevention in men at increased risk for prostate can-
cer. Resource use datawas prospectively collected and included drugs, procedures,
outpatient visits, and inpatient visits in general and those associated with related
conditions such as hematuria, hematospermia, acute urinary retention, urinary
tract infection, benign prostatic hyperplasia, and prostate cancer. Unit costs from
standard costing sources were applied to resource use incurred during the trial.
Quality-adjusted life-years (QALYs) were calculated on the basis of men being
healthy and having BPH, prostate cancer, and adverse events. Utilities were ob-
tained from the published literature. Incremental costs per QALY were calculated.
Bootstrap analyses, to derive cost-effectiveness acceptability curves, were per-
formed. The analysis was performed from the perspective of a US health care
payer. RESULTS: Men using dutasteride incurred a mean cost of $6,610 (including
cost of dutasteride) whereas men in the placebo group incurred a mean cost of
$3,177 over the 4-year period of the trial. Men using dutasteride accrued 0.13 more
QALYs than men on placebo (3.26 vs. 3.13). As a result, the use of dutasteride as a
chemoprevention was cost-effective (incremental cost per QALY $50,000), with
an incremental cost per QALY of $26,516. The incremental cost per prostate cancer
avoided was $19. CONCLUSIONS: Using dutasteride as a chemoprevention for
prostate cancer in men at increased risk, as seen in the REDUCE trial, is cost-
effective. These cost-effective benefits of chemoprevention are realizable in a pe-
riod of time as short as 4 years.
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OBJECTIVES: To help facilitate economic evaluations of interventions for treating
cancer, we estimated utility indices for the two frequently used cancer-specific
(FACT-G and EORTC-QLQ-C30) instruments of quality-of-life, by mapping them
onto each of the EQ-5D and SF-6D preference-based-indices.METHODS: A sample
of 367 cancer patients from the Vancouver Cancer Centre completed four health-
related-quality-of-life questionnaires (EORTC-QLQ-C30/FACT-G/EQ-5D/SF-6D).
The sample was randomly divided to provide development(n184) and cross-vali-
dation(n183) samples. Models of the relationships between the EORTC-QLQ-C30/
FACT-G and each of the preference-based-indices were estimated using regression
analyses. We examined three alternative modeling approaches: ordinary-least-
squares(OLS); generalized-linear-modeling(GLM) using aGaussian distribution and
log-link; and censored-least-absolute deviations(CLAD). The performance of the
models was assessed in terms of how well the responses to the cancer-specific
instruments predicted utilities from each of the EQ-5D/SF-6D instruments.
RESULTS: The CLAD approach considers the non-normal(left-skew) distribution of
the utility scores and their apparent truncation at one. Results from the final mod-
els of the three approaches did not differ significantly. Physical, functional and
emotional well-being domain-scores of FACT-G significantly predict EQ-5D/SF-6D
utility scores. Physical and emotional functioning and pain subscales of the
EORTC-QLQ-C30 were significant predictors of the utility scores. Cognitive func-
tioning and insomnia subscales of the EORTC-QLQ-C-30 were significantly associ-
ated with the EQ-5D, while the social and role functioning, and fatigue were only
significant predictors of the SF-6D utility-index. The addition of age, gender, stage
of disease, and ethnicity did not lead to significant improvement in themodel. The
root mean square error(RMSE) for the SF-6D was lower (0.064), suggesting better
predictions than for the EQ-5D(0.098). CONCLUSIONS: There is potential to esti-
mate EQ-5D/SF-6D utilities using responses from the cancer-specific FACT-G/
EORTC-QLQ-C-30 measures of quality-of-life, even though the latter were not de-
signed as utility instruments. Our results suggest that it is possible to estimate
Quality-Adjusted-Life-Years(QALYs) from studies where only cancer-specific in-
struments have been administered.
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